"Betting the farm and waiting for the next blockbuster is not going to work," sanofi-aventis
Sanofi's collaboration with Regeneron Pharmaceuticals
... the problem with drugmakers' R&D isn't a lack of money but a failure to exploit innovative thinking. To that end [Viehbacher] is changing the structure of the research labs, from monoliths to smaller units that are either entrepreneurial (racing to develop a drug) or exploratory (looking for new biology to study).
Blockbusters have been harder to come by. Is Viehbacher's solution the way for Sanofi and competitors like Pfizer
Sound off in the comments box below.